Brief: Viveve Medical Inc - Company Will Seek Strategic Alternatives And Will Be Delisted From Nasdaq

Viveve Medical

17/01/2023 12:06

Jan 17 (Reuters) - Viveve Medical Inc  VIVE.O :
    * VIVEVE MEDICAL INC - COMPANY WILL SEEK STRATEGIC
ALTERNATIVES
AND WILL BE DELISTED FROM NASDAQ
    * VIVEVE MEDICAL INC - COMPANY HAS IMPLEMENTED A REDUCTION
IN
FORCE
    * VIVEVE MEDICAL INC - ON JANUARY 14, 2023, BOARD OF
DIRECTORS OF
CO APPROVED A REDUCTION OF THE COMPANY’S WORKFORCE
    * VIVEVE MEDICAL INC - COMPANY EXPECTS TO RECORD A CHARGE OF
APPROXIMATELY $25,000 IN THE FIRST QUARTER OF 2023 RELATING TO
THE REDUCTION IN FORCE
    * VIVEVE MEDICAL INC - WILL CONTINUE TO RE-EVALUATE
ESTIMATED
COSTS AND EXPENSES AND MAY REVISE ESTIMATED RESTRUCTURING CHARGE
AS APPROPRIATE
    * VIVEVE MEDICAL INC - VIVEVE ANNOUNCES TOPLINE RESULTS FROM
PIVOTAL U.S. PURSUIT TRIAL FOR TREATING FEMALE STRESS URINARY
INCONTINENCE
    * VIVEVE MEDICAL INC - STUDY'S PRIMARY EFFICACY ENDPOINT WAS
NOT
ACHIEVED AT 12 MONTHS POST-TREATMENT
    * VIVEVE MEDICAL INC -  STUDY DID NOT MEET SEVERAL SECONDARY
ENDPOINTS
    * VIVEVE MEDICAL INC - INTENDS TO EXPLORE STRATEGIC OPTIONS,
INCLUDING SALE OF CO’S BUSINESS OR ASSETS, AND/OR WIND-DOWN OF
CO’S OPERATIONS
    * VIVEVE MEDICAL INC -  STUDY ALSO DID NOT MEET SEVERAL
SECONDARY
ENDPOINTS
    * VIVEVE MEDICAL INC - THERE WERE NO SERIOUS DEVICE-RELATED
ADVERSE EVENTS REPORTED IN STUDY

Source text for Eikon: [ID:http://bit.ly/3IW2tc4]
Further company coverage:  VIVE.O 
 ((Reuters.Briefs@thomsonreuters.com;))